Home >> WEBINARS >> Resectability in stage III NSCLC:
Case-based considerations for clinical decision making

Resectability in stage III NSCLC:
Case-based considerations for clinical decision making

Print Friendly, PDF & Email

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Webinar presenters Michael Walker, MD, System Chief, Thoracic Surgery, Medical Director, Cancer Program, Main Line Health, and Tracey Evans, MD, Director, Thoracic Oncology Research, Co-Director, Thoracic Oncology Program, Associate Program Director, Hematology/Medical Oncology Fellowship Program, Lankenau Cancer Center, discuss AJCC staging guidelines for lung cancer, specifically Stage III disease. This on-demand webinar originally broadcast on November 14, 2018.

CAP TODAY does not endorse any of the products or services named within.
©2018 AstraZeneca. All rights reserved. US-23324 Last Updated 9/18

IMFINZI® (durvalumab) Prescribing Information Link  Prescribing Information

x

Check Also

Homologous recombination deficiency and BRCA testing in ovarian and breast cancer

Webinar presenters Dana Chase, MD,  Michelle Shiller, DO, and Tabetha Sundin, PhD discuss the role of BRCA1/2 mutations in homologous recombination deficiency and carcinogenesis, homologous recombination deficiency as a marker of treatment sensitivity, the testing process for homologous recombination deficiency and BRCA mutations, and the role of BRCA testing in ovarian and breast cancer. This on-demand webinar originally broadcast on October 23, 2018.

X